For the next two weeks, a digital poster campaign will be featured in London asking the UK public “Could magic mushrooms be medicine?”.
Tadeusz Hawrot, Founder and Executive Director of the Psychedelic Access and Research European Alliance (PAREA), speaks to Psychedelic Health about how the organisation plans to campaign...
Canadian non-profit TheraPsil has announced that patients and medical professionals from across Canada will be reaching out to Parliamentarians to raise awareness of the medical benefits...
Awakn CEO, Anthony Tennyson, spoke to Psychedelic Health about the company’s plans to make ketamine therapy accessible to US patients.
Optimi Health has launched Blue Serenity – Canada’s first natural therapeutic psilocybin product, in collaboration with psilocybin patient advocate Thomas Hartle.
In a move that aims to provide patients in Canada with the “life-changing opportunity” to receive psilocybin-assisted psychotherapy, TheraPsil and Drug Science are collaborating to launch...
Backed by three top psychiatrists, 161 cluster headache sufferers in the UK have written an open letter to Home Office ministers Savid Javid and Kit Malthouse...
Awakn has signed a Memorandum of Understanding (MOU) with the Devon Partnership NHS Trust and the University of Exeter to increase access to psychedelic-assisted therapy for...
The first ketamine clinic in the UK has received approval from the Care Quality Commission (CQC) to begin treatments.
The End in Mind conference will bring together celebrities, healthcare and psychedelics experts and policy makers to explore the role that psychedelics can play in the...
